全部产品 / DC8546
MI-136
产品概要
MI-136 抑制DHT诱导的雄激素受体(AR)靶基因表达。靶点:雄激素受体。体外:MI-136是此前报道的一种抑制剂的变体,可特异性抑制menin–MLL相互作用。VCaP、LNCaP和22RV1等AR阳性细胞系对MI-136敏感。MI-136处理也抑制AR刺激后与ASH2L结合的基因表达。PARP裂解(cPARP)表明,MI-136处理可诱导VCaP细胞凋亡。此外,MI-136处理阻断AR依赖细胞系(LNCaP和VCaP)中DHT诱导的细胞增殖。MI-136对细胞增殖的作用与MDV-3100相似;后者是获FDA批准、用于难治性前列腺癌患者的第二代抗雄激素药物[1]。体内:用MI-136(40 mg/kg)处理荷VCaP肿瘤的小鼠,可使肿瘤体积中等程度但显著减小,且不影响小鼠体重[1]。
仅供科研使用。研究结果取决于实验条件,不构成产品性能保证。
产品身份与规格
| 目录号 | DC8546 |
|---|---|
| 产品名称 | MI-136 |
| CAS | 1628316-74-4 |
| 分子式 | C23N6F3SH21 |
| 分子量 | 470.5132 |
| 纯度 | 99% |
| SMILES | S1C(C([H])([H])C(F)(F)F)=C([H])C2C1=NC([H])=NC=2N([H])C1([H])C([H])([H])C([H])([H])N(C([H])([H])C2C([H])=C([H])C3=C(C([H])=C(C#N)N3[H])C=2[H])C([H])([H])C1([H])[H] |
来源列示的产品规格;具体要求以批次 COA 为准。
原始研究与产品文件
详细实验条件、性能数据和参考文献请参见英文原始资料。COA、SDS及批次文件请向客服索取。
英文原始产品资料原文参考文献
MI-136 inhibits DHT-induced expression of androgen receptor (AR) target genes. Target: androgen receptorin vitro: MI-136, a variant of a previously described inhibitor that can specifically inhibit the menin-MLL interaction. AR positive cell lines such as VCaP, LNCaP and 22RV1 are sensitive to MI-136. Treatment with MI-136 also inhibits the expression of genes that were bound to ASH2L after AR stimulation. Treatment with MI-136 induces apoptosis of VCaP cells as evidenced by PARP (cPARP) cleavage. Furthermore, treatment with MI-136 blocks DHT-induced cell proliferation in AR-dependent cell lines (LNCaP and VCaP). The effect of MI-136 on cell proliferation is similar to MDV-3100, a second-generation FDA-approved anti-androgen for patients with refractory prostate cancer. [1]in vivo: Treatment of VCaP tumor-bearing mice with MI-136 (40mg/kg) led to a modest but significant reduction in tumor volume with no effect on mouse body weight. [1]
